摘要
Abstract
Objective To observe the clinical efficacy and safety of trimetazidine tablets in the treatment of chronic heart failure.Methods A total of 123 patients with chronic heart failure were randomized into control group(n =61 cases) and treatment group (n =61 cases).Control group was givenaspirin 100 mg,qd,oral + atorvastatin calcium 20 mg,qn,oral + perindopril 4 mg,qd,oral + metoprolol succinate sustained-release tablets 47.5 mg,qd,oral.Treatment group was given trimetazidine 20 mg,tid,oral,on the basis of control group.Two groups were treated for 6 months.The clinical efficacy,left ventricular ejection fraction(LVEF),6-minute walking test,brain natriuretic peptide (BNP)and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 80.65％ (50/62 cases) and 72.13％ (44/61 cases) without significant difference (P＞0.05).After treatment,the main indexes in treatment and control groups were compared:the LVEF were (38.85 ± 4.72)％,(36.53 ±3.10)％;walking distances during 6 min were (375.23 ±43.84),(344.64 ± 38.92) m;BNP were (335.48 ± 211.36),(420.52 ± 237.47) pg · mL-1,the differences were statistically significant (all P ＜0.05).The adverse drug reactions in treatment group were based on nausea,vomiting and skin itching,which in treatment group were nausea and stomach discomfort.The incidences of adverse drug reactions in treatment and control groups were 6.45％ and 3.27％ without significant difference (P ＞ 0.05).Conclusion Trimetazidine tablets can not significantly improve the clinical efficacy in the treatment of chronic heart failure,but it can significantly improve the patient's cardiac function and exercise tolerance,reduce the level of BNP,without increasing the incidence of adverse drug reactions.关键词
曲美他嗪片/冠心病心力衰竭/安全性Key words
trimetazidine tablet/chronic heart failure/safety分类
医药卫生
